Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma

Michele Merli, Giuseppe Carli, Luca Arcaini, Carlo Visco

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

The association of hepatitis C virus (HCV) and B-cell non-Hodgkin lymphomas (NHL) has been highlighted by several epidemiological and biological insights; however the most convincing evidence is represented by interventional studies demonstrating the capability of antiviral treatment (AT) with interferon (IFN) with or without ribavirin to induce the regression of indolent lymphomas, especially of marginal-zone origin. In the largest published retrospective study (100 patients) the overall response rate (ORR) after first-line IFN-based AT was 77% (44% complete responses) and responses were sustainable (median duration of response 33 mo). These results were confirmed by a recent metaanalysis on 254 patients, demonstrating an ORR of 73%. Moreover this analysis confirmed the highly significant correlation between the achievement of viral eradication sustained virological response (SVR) and hematological responses. Two large prospective studies demonstrated that AT is associated with improved survival and argue in favor of current guidelines' recommendation of AT as preferential first-line option in asymptomatic patients with HCV-associated indolent NHL. The recently approved direct-acting antiviral agents (DAAs) revolutionized the treatment of HCV infection, leading to SVR approaching 100% in all genotypes. Very preliminary data of IFN-free DAAs therapy in indolent HCV-positive NHL seem to confirm their activity in inducing lymphoma regression.

Original languageEnglish
Pages (from-to)8447-8458
Number of pages12
JournalWorld Journal of Gastroenterology
Volume22
Issue number38
DOIs
Publication statusPublished - Oct 14 2016

Fingerprint

B-Cell Lymphoma
Hepatitis C
Antiviral Agents
Hepacivirus
Non-Hodgkin's Lymphoma
Interferons
Lymphoma
Therapeutics
Ribavirin
Virus Diseases
Hepatitis B
Retrospective Studies
Genotype
Prospective Studies
Guidelines
Survival

Keywords

  • Antiviral therapy
  • Direct-acting antiviral agents
  • Hepatitis C virus
  • Interferon
  • Marginal zone lymphomas
  • Non-hodgkin lymphomas
  • Ribavirin
  • Sofosbuvir

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma. / Merli, Michele; Carli, Giuseppe; Arcaini, Luca; Visco, Carlo.

In: World Journal of Gastroenterology, Vol. 22, No. 38, 14.10.2016, p. 8447-8458.

Research output: Contribution to journalReview article

Merli, Michele ; Carli, Giuseppe ; Arcaini, Luca ; Visco, Carlo. / Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma. In: World Journal of Gastroenterology. 2016 ; Vol. 22, No. 38. pp. 8447-8458.
@article{fb3ef977795e49a59102035e2f2adf30,
title = "Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma",
abstract = "The association of hepatitis C virus (HCV) and B-cell non-Hodgkin lymphomas (NHL) has been highlighted by several epidemiological and biological insights; however the most convincing evidence is represented by interventional studies demonstrating the capability of antiviral treatment (AT) with interferon (IFN) with or without ribavirin to induce the regression of indolent lymphomas, especially of marginal-zone origin. In the largest published retrospective study (100 patients) the overall response rate (ORR) after first-line IFN-based AT was 77{\%} (44{\%} complete responses) and responses were sustainable (median duration of response 33 mo). These results were confirmed by a recent metaanalysis on 254 patients, demonstrating an ORR of 73{\%}. Moreover this analysis confirmed the highly significant correlation between the achievement of viral eradication sustained virological response (SVR) and hematological responses. Two large prospective studies demonstrated that AT is associated with improved survival and argue in favor of current guidelines' recommendation of AT as preferential first-line option in asymptomatic patients with HCV-associated indolent NHL. The recently approved direct-acting antiviral agents (DAAs) revolutionized the treatment of HCV infection, leading to SVR approaching 100{\%} in all genotypes. Very preliminary data of IFN-free DAAs therapy in indolent HCV-positive NHL seem to confirm their activity in inducing lymphoma regression.",
keywords = "Antiviral therapy, Direct-acting antiviral agents, Hepatitis C virus, Interferon, Marginal zone lymphomas, Non-hodgkin lymphomas, Ribavirin, Sofosbuvir",
author = "Michele Merli and Giuseppe Carli and Luca Arcaini and Carlo Visco",
year = "2016",
month = "10",
day = "14",
doi = "10.3748/wjg.v22.i38.8447",
language = "English",
volume = "22",
pages = "8447--8458",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "38",

}

TY - JOUR

T1 - Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma

AU - Merli, Michele

AU - Carli, Giuseppe

AU - Arcaini, Luca

AU - Visco, Carlo

PY - 2016/10/14

Y1 - 2016/10/14

N2 - The association of hepatitis C virus (HCV) and B-cell non-Hodgkin lymphomas (NHL) has been highlighted by several epidemiological and biological insights; however the most convincing evidence is represented by interventional studies demonstrating the capability of antiviral treatment (AT) with interferon (IFN) with or without ribavirin to induce the regression of indolent lymphomas, especially of marginal-zone origin. In the largest published retrospective study (100 patients) the overall response rate (ORR) after first-line IFN-based AT was 77% (44% complete responses) and responses were sustainable (median duration of response 33 mo). These results were confirmed by a recent metaanalysis on 254 patients, demonstrating an ORR of 73%. Moreover this analysis confirmed the highly significant correlation between the achievement of viral eradication sustained virological response (SVR) and hematological responses. Two large prospective studies demonstrated that AT is associated with improved survival and argue in favor of current guidelines' recommendation of AT as preferential first-line option in asymptomatic patients with HCV-associated indolent NHL. The recently approved direct-acting antiviral agents (DAAs) revolutionized the treatment of HCV infection, leading to SVR approaching 100% in all genotypes. Very preliminary data of IFN-free DAAs therapy in indolent HCV-positive NHL seem to confirm their activity in inducing lymphoma regression.

AB - The association of hepatitis C virus (HCV) and B-cell non-Hodgkin lymphomas (NHL) has been highlighted by several epidemiological and biological insights; however the most convincing evidence is represented by interventional studies demonstrating the capability of antiviral treatment (AT) with interferon (IFN) with or without ribavirin to induce the regression of indolent lymphomas, especially of marginal-zone origin. In the largest published retrospective study (100 patients) the overall response rate (ORR) after first-line IFN-based AT was 77% (44% complete responses) and responses were sustainable (median duration of response 33 mo). These results were confirmed by a recent metaanalysis on 254 patients, demonstrating an ORR of 73%. Moreover this analysis confirmed the highly significant correlation between the achievement of viral eradication sustained virological response (SVR) and hematological responses. Two large prospective studies demonstrated that AT is associated with improved survival and argue in favor of current guidelines' recommendation of AT as preferential first-line option in asymptomatic patients with HCV-associated indolent NHL. The recently approved direct-acting antiviral agents (DAAs) revolutionized the treatment of HCV infection, leading to SVR approaching 100% in all genotypes. Very preliminary data of IFN-free DAAs therapy in indolent HCV-positive NHL seem to confirm their activity in inducing lymphoma regression.

KW - Antiviral therapy

KW - Direct-acting antiviral agents

KW - Hepatitis C virus

KW - Interferon

KW - Marginal zone lymphomas

KW - Non-hodgkin lymphomas

KW - Ribavirin

KW - Sofosbuvir

UR - http://www.scopus.com/inward/record.url?scp=84991109544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991109544&partnerID=8YFLogxK

U2 - 10.3748/wjg.v22.i38.8447

DO - 10.3748/wjg.v22.i38.8447

M3 - Review article

AN - SCOPUS:84991109544

VL - 22

SP - 8447

EP - 8458

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 38

ER -